Liminal BioSciences (LMNL) Reports First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

Liminal BioSciences Inc. (NASDAQ: LMNL) today announced that the first subject has been dosed in the Company's fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.

The new clinical trial is designed to look at more frequent daily dosing (twice and three times daily) of fezagepras up to 2,400mg for a total of 14 days. The clinical trial is a standard placebo-controlled Phase 1 ascending dose design in healthy volunteers. The clinical trial endpoints will include safety, pharmacokinetics, and exploratory biomarkers related to the mechanism of action of fezagepras. The data from this clinical trial will be used to guide selection of the appropriate dose and dosing frequency of fezagepras for anticipated future clinical trials.

"We are conducting this clinical trial with fezagepras to help define the optimal dosing regimen that we expect to take forward into phase 2 clinical development in patients with idiopathic pulmonary fibrosis (IPF)", said Bruce Pritchard, Chief Executive Officer of Liminal BioSciences.

You May Also Be Interested In

• Acrivon Therapeutics (ACRV) Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
• Whirlpool (WHR) to cut 1,000 jobs - CFO Jim Peters
• Abeona Therapeutics (ABEO) Receives FDA Complete Response Letter on Pz-cel